Doxorubicin Cardiomyopathy

被引：849

作者：

Chatterjee, Kanu ^{[1
]}

Zhang, Jianqing ^{[2
]}

Honbo, Norman ^{[2
]}

Karliner, Joel S. ^{[2
,3
]}

机构：

[1] Univ Iowa, Dept Med, Carver Coll Med, Div Cardiol, Iowa City, IA 52242 USA

[2] Univ Calif San Francisco, VA Med Ctr, Cardiol Sect, San Francisco, CA 94143 USA

[3] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA

来源：

CARDIOLOGY | 2010年 / 115卷 / 02期

关键词：

Adriamycin; Anthracyclines; Cardiomyocytes; Cardiomyopathy; Doxorubicin; Vincristine; ADRIAMYCIN-INDUCED CARDIOMYOPATHY; CONGESTIVE-HEART-FAILURE; NITRIC-OXIDE SYNTHASE; RAT CARDIAC MYOCYTES; INDUCED APOPTOSIS; ANTHRACYCLINE ANTIBIOTICS; INDUCED CARDIOTOXICITY; RADICAL FORMATION; BREAST-CANCER; TOXICITY;

D O I：

10.1159/000265166

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. Extensive research has been done and is being done to discover preventive treatments. However an effective and clinically applicable preventive treatment is yet to be discovered. Copyright (C) 2009 S. Karger AG, Basel

引用

页码：155 / 162

页数：8

共 62 条

[1]

ARENA E, 1979, ARZNEIMITTEL-FORSCH, V29-1, P901

[2] LONG-TERM SURVIVAL AFTER HEART-TRANSPLANTATION FOR DOXORUBICIN INDUCED CARDIOMYOPATHY [J].

ARICO, M ;

PEDRONI, E ;

NESPOLI, L ;

VIGANO, M ;

PORTA, F ;

BURGIO, GR .

ARCHIVES OF DISEASE IN CHILDHOOD, 1991, 66 (08) :985-986

[3] Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity [J].

Aries, A ;

Paradis, P ;

Lefebvre, C ;

Schwartz, RJ ;

Nemer, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (18) :6975-6980

[4] Canadian Cardiovascular Society Consensus Conference guidelines on heart failure-2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies [J].

Arnold, J. Malcolm O. ;

Howlett, Jonathan G. ;

Ducharme, Anique ;

Ezekowitz, Justin A. ;

Gardner, Martin J. ;

Giannetti, Nadia ;

Haddad, Haissarn ;

Heckman, George A. ;

Isaac, Debra ;

Jong, Philip ;

Liu, Peter ;

Mann, Elizabeth ;

McKelvie, Robert S. ;

Moe, Gordon W. ;

Svendsen, Anna M. ;

Tsuyuki, Ross T. ;

O'Halloran, Kelly ;

Ross, Heather J. ;

Sequeira, Errol J. ;

White, Michel .

CANADIAN JOURNAL OF CARDIOLOGY, 2008, 24 (01) :21-40

[5]

Arola OJ, 2000, CANCER RES, V60, P1789

[6] NADPH CYTOCHROME-P-450 REDUCTASE ACTIVATION OF QUINONE ANTI-CANCER AGENTS TO FREE-RADICALS [J].

BACHUR, NR ;

GORDON, SL ;

GEE, MV ;

KON, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (02) :954-957

[7]

BERLIN V, 1981, J BIOL CHEM, V256, P4747

[8] The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy [J].

Bien, Sandra ;

Riad, Alexander ;

Ritter, Christoph A. ;

Gratz, Matthias ;

Shausen, Florian ;

Westermann, Dirk ;

Grube, Markus ;

Krieg, Thomas ;

Ciecholewski, Sabine ;

Felix, Stephan B. ;

Staudt, Alexander ;

Schultheiss, Heinz-Peter ;

Ewert, Ralf ;

Volker, Uwe ;

Tschöpe, Carsten ;

Kroemer, Heyo K. .

CANCER RESEARCH, 2007, 67 (21) :10428-10435

[9]

BILLINGHAM ME, 1978, CANCER TREAT REP, V62, P865

[10] ACUTE AND CHRONIC CARDIOVASCULAR EFFECTS OF DOXORUBICIN IN THE DOG - THE CARDIOVASCULAR PHARMACOLOGY OF DRUG-INDUCED HISTAMINE-RELEASE [J].

BRISTOW, MR ;

SAGEMAN, WS ;

SCOTT, RH ;

BILLINGHAM, ME ;

BOWDEN, RE ;

KERNOFF, RS ;

SNIDOW, GH ;

DANIELS, JR .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1980, 2 (05) :487-515

← 1 2 3 4 5 6 7 →